Amgen, NPS start AMG 073 Phase III

NPS Pharmaceuticals (NPSP) licensee AMGN began a Phase III trial of AMG 073, an oral calcimimietic, to treat secondary hyperparathyroidism, a disorder caused by renal disease. The start of the trial t...